{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immune+checkpoint+inhibitor&page=10", "query": { "intervention": "Immune checkpoint inhibitor", "page": 10 }, "page_size": 10 }, "pagination": { "page": 10, "page_size": 10, "total_count": 371, "total_pages": 38, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immune+checkpoint+inhibitor&page=11&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immune+checkpoint+inhibitor&page=9&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T12:53:41.387Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02664181", "title": "Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer", "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "oral decitabine", "type": "DRUG" }, { "name": "Tetrahydrouridine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2017-06-06", "completion_date": "2024-05-19", "has_results": true, "last_update_posted_date": "2024-09-03", "last_synced_at": "2026-11-15T12:53:41.387Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Cleveland, Ohio", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02664181" }, { "nct_id": "NCT03535545", "title": "Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pulmonary Fibrosis", "Lung Cancer" ], "interventions": [ { "name": "[68Ga]CBP8", "type": "DRUG" }, { "name": "PET Imaging", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 100, "start_date": "2018-08-01", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-11-15T12:53:41.387Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03535545" }, { "nct_id": "NCT04701476", "title": "TATE and Pembrolizumab (MK3475) in mCRC and NSCLC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer; Lung Cancer" ], "interventions": [ { "name": "TATE and pembrolizumab", "type": "DRUG" }, { "name": "TAS-102 pill", "type": "DRUG" }, { "name": "Regorafenib Pill", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teclison Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 110, "start_date": "2021-05-20", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-04-16", "last_synced_at": "2026-11-15T12:53:41.387Z", "location_count": 1, "location_summary": "Orange, California", "locations": [ { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04701476" }, { "nct_id": "NCT06340568", "title": "A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Endometrial Cancer" ], "interventions": [ { "name": "BNT323/DB-1303", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 480, "start_date": "2025-06-10", "completion_date": "2029-11", "has_results": false, "last_update_posted_date": "2026-11-10", "last_synced_at": "2026-11-15T12:53:41.387Z", "location_count": 22, "location_summary": "Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 19 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06340568" }, { "nct_id": "NCT06146920", "title": "Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Melanoma", "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Evaluation of ctDNA using the F1T after 1 year of immunotherapy", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2024-01-10", "completion_date": "2028-11", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-11-15T12:53:41.387Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06146920" }, { "nct_id": "NCT03173950", "title": "Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Medulloblastoma", "Ependymoma", "Pineal Region Tumors", "Choroid Plexus Tumors", "Atypical/Malignant Meningioma" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI Brain and/or spine", "type": "DIAGNOSTIC_TEST" }, { "name": "Body CT Scan", "type": "DIAGNOSTIC_TEST" }, { "name": "MDASI-BT", "type": "OTHER" }, { "name": "MDASI-SP", "type": "OTHER" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 136, "start_date": "2017-07-13", "completion_date": "2025-06-23", "has_results": true, "last_update_posted_date": "2026-10-27", "last_synced_at": "2026-11-15T12:53:41.387Z", "location_count": 3, "location_summary": "Chicago, Illinois • Bethesda, Maryland • Houston, Texas", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03173950" }, { "nct_id": "NCT05538091", "title": "Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "PARP Inhibitor", "Hedgehog Inhibitor" ], "interventions": [ { "name": "Vismodegib", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ronald Buckanovich", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 48, "start_date": "2023-05-15", "completion_date": "2032-09-30", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-11-15T12:53:41.387Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05538091" }, { "nct_id": "NCT04691817", "title": "Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lung Cancer, Nonsmall Cell" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2023-07-25", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-01-07", "last_synced_at": "2026-11-15T12:53:41.387Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04691817" }, { "nct_id": "NCT06745908", "title": "Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "NSCLC Stage IV" ], "interventions": [ { "name": "N-803", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Prior failed checkpoint inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 507, "start_date": "2025-10-01", "completion_date": "2029-01", "has_results": false, "last_update_posted_date": "2026-11-02", "last_synced_at": "2026-11-15T12:53:41.387Z", "location_count": 32, "location_summary": "Hot Springs, Arkansas • Springdale, Arkansas • El Segundo, California + 26 more", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "El Segundo", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06745908" }, { "nct_id": "NCT07830225", "title": "A Pilot Study of ctDNA-Guided Immune Checkpoint Inhibitor Duration in Patients With Advanced Melanoma.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Melanoma (Skin Cancer)" ], "interventions": [ { "name": "A Pilot Study of ctDNA-guided immune checkpoint inhibitor duration in patients with advanced melanoma", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 35, "start_date": "2026-09-03", "completion_date": "2029-06-30", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-11-15T12:53:41.387Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT07830225" } ] }